Tracker
Ten clinical trials to watch through the end of the year
Readouts in Alzheimer's disease, heart failure and pancreatic cancer will shape pipelines and share prices over the coming months.
By Lena FischerPublished · Updated Oct. 2, 2026 · 1 min read
Late-stage results are the events that most reliably move this industry, and the back half of the year is unusually dense with them. We are tracking ten.
| Sponsor | Area | Phase | Expected |
|---|---|---|---|
| Marrow Peak | Multiple myeloma | 3 | October |
| Ionwell | Obesity, muscle preservation | 2b | October |
| Brightwater Oncology | Pancreatic cancer | 3 | November |
| Nordlicht Pharma | Heart failure | 3 | November |
| Sundari Life Sciences | Early Alzheimer's disease | 3 | November |
| Palisade Rx | Chronic kidney disease | 3 | December |
| Tessaly Genomics | Sickle cell disease | 1/2 | December |
| Quillon Biosciences | Crohn's disease | 3 | December |
| Halvern Therapeutics | Lung cancer, first line | 3 | December |
| Corvane Bio | Rare metabolic disorder | 3 | Early 2027 |
The ones that matter most
Sundari in Alzheimer's. The company's oral drug targets inflammation rather than amyloid. A positive result would be the first for that approach in a pivotal trial. Most analysts put the odds below one in four.
Brightwater in pancreatic cancer. An interim look in the spring allowed the study to continue unchanged, which investors read as mildly encouraging. Median survival in the control arm is expected to be about eleven months.
Nordlicht in heart failure. The trial enrolled 6,200 patients and is the largest on this list. It is designed to show a reduction in hospitalizations and cardiovascular death.
We will update this page as results arrive.
